Swiss Biopharma Lumavita Extends Series A Round
Lumavita AG, a Swiss developer of anti-infectives for women's health, has raised CHF 6 million ($5.53m) in new Series A funding. The round total is now CHF 24 million ($22m). HealthCap led the tranche, and was joined by return backer Endeavour Vision.
19 June 2009•2 mins read
